drugset / Trial / NCT05705388
POSE2.0 With GLP-1 Agonist for Obesity Management
RandomizedCrossoverOpen-labelTreatment
Summary
Determine the effect on weight loss and obesity-related comorbidities in patients receiving the POSE 2.0 procedure with sequential use of Liraglutide at 6 months compared to those receiving Liraglutide and then undergoing the POSE 2.0 procedure at 6 months.
Timeline
- Start
- 2023-01-16
- Primary completion
- 2025-01-03
- Completion
- 2026-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Liraglutide | Peptide | 3 mg | Subcutaneous |